News about Global Pharma

Vincerx Pharma Signs Binding Term Sheet for a Strategic Merger with Oqory

Vincerx is also implementing additional streamlining and cost-control measures, including a workforce reduction, as it pursues due diligence and transaction-related work.

Global Pharma | 31/12/2024 | By Aishwarya |  439

Precigen Completes Submission for BLA to USFDA for PRGN-2012

The submission is in the initial 60 day review period, during which time the FDA will decide whether to accept the BLA for further review and set the Prescription Drug User Fee Act (PDUFA) action date.

Global Pharma | 30/12/2024 | By Manvi |  437

USFDA Approves Bristol Myers Squibb's 'Opdivo Qvantig Injection'

Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) granted approval for Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use, a combination product of nivolumab co-formulated with recombinant human hyaluronidase (rHuPH20).

Global Pharma | 30/12/2024 | By Manvi |  220

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849

IDEAYA Biosciences has secured an exclusive global license (outside China) from Jiangsu Hengrui Pharmaceuticals for SHR-4849, a novel DLL3-targeting ADC program with promising early clinical results in solid tumours, including small cell lung cancer.

Global Pharma | 30/12/2024 | By Manvi |  218

Hoth Therapeutics Partners with the Department of Veterans Affairs to Develop Obesity Treatment

Hoth Therapeutics, Inc., a biopharmaceutical company, has secured an exclusive patent license agreement with the US Department of Veterans Affairs and Emory University for groundbreaking technology targeting obesity and related health conditions.

Global Pharma | 27/12/2024 | By Manvi |  116

AusperBio Bags USD 73 Million in Series B Financing for Chronic Hepatitis B

This financing followed the company's Series A round completed in July this year, demonstrating continued investor confidence in its proprietary platform and strategic direction.

Global Pharma | 27/12/2024 | By Aishwarya |  260

Meiji Seika Pharma Establishes Local Subsidiary Taiwan Meiji Pharma

Meiji Seika Pharma aims to become ‘a company in Asia in the field of infectious diseases’ as part of the ‘Meiji Group 2026 Vision’ targeting the year 2026.

Global Pharma | 26/12/2024 | By Aishwarya |  668

Bio-Thera Solutions, Tabuk Pharmaceutical Partner to Commercialise BAT2206 in Saudi Arabia

Bio-Thera Solutions Inc. has partnered with Tabuk Pharmaceutical Manufacturing Company, a fully-owned subsidiary of Astra Industrial Group, for BAT2206, its ustekinumab biosimilar.

Global Pharma | 26/12/2024 | By Abha |  981

Ractigen Therapeutics Doses First Patient in Phase I Clinical Trial for RAG-17 in SOD1-ALS

RAG-17 received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) in March 2023, followed by the FDA's clearance of its Investigational New Drug (IND) application.

Global Pharma | 26/12/2024 | By Aishwarya |  649

Porton Pharma Solutions and Dragon Sail Pharmaceutical Partner to Advance ADC Drug Ecosystem

This collaboration aims to carry out in-depth cooperation in the research, development, production, and supply chain integration of antibody-drug conjugates (ADC).

Global Pharma | 24/12/2024 | By Manvi |  606